96 results
8-K
EX-99.1
LYEL
Lyell Immunopharma, Inc.
7 Aug 24
Lyell Immunopharma Reports Business Highlights and Financial Results for the Second Quarter 2024
4:06pm
; the potential clinical benefits and therapeutic potential of Lyell’s product candidates; the advancement of Lyell’s technology platform; Lyell’s
424B5
LYEL
Lyell Immunopharma, Inc.
6 May 24
Prospectus supplement for primary offering
8:12am
suffer from the diseases we target and the number of subjects that may enroll in our clinical trials;
the benefits associated with the U.S. Food … exemptions and potential seven-year marketing exclusivity upon FDA approval and comparable benefits associated with foreign ODDs in other countries
8-K
EX-99.1
LYEL
Lyell Immunopharma, Inc.
6 May 24
Lyell Immunopharma Reports Business Highlights and Financial Results for the First Quarter 2024
8:03am
, development and clinical capabilities; the potential clinical benefits and therapeutic potential of Lyell’s product candidates; the advancement of Lyell’s … capital to achieve its goals; anticipated benefits and financial impact of Lyell’s workforce restructuring; and other risks, including those described
S-3
uobpf43dak9zow7 fwb0
28 Feb 24
Shelf registration
7:49pm
S-3
EX-4.8
2lfbzlcuy2z
28 Feb 24
Shelf registration
7:49pm
S-3
EX-4.5
er1di6l 6r5q5v
28 Feb 24
Shelf registration
7:49pm
S-3
EX-1.2
weqmpz 43o
28 Feb 24
Shelf registration
7:49pm
S-3
EX-4.7
d4v gm5o761vp9t9hhvd
28 Feb 24
Shelf registration
7:49pm
S-3
EX-4.9
eepp6jbt7bhe
28 Feb 24
Shelf registration
7:49pm
8-K
EX-99.1
wrvxpwyg3knj25b
28 Feb 24
Lyell Immunopharma Reports Business Highlights and Financial Results for the Fourth Quarter and Full Year 2023
4:07pm
8-K
EX-99.1
55ulw3 uqfr7du3
7 Nov 23
Lyell Immunopharma Reports Business Highlights and Financial Results for the Third Quarter 2023
4:08pm